NLTX News and Press, Neoleukin Therapeutics Inc. From 12/12/22

SEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of th...

Nanocap biotech Neoleukin Therapeutics ( NASDAQ: NLTX ) shed ~19% pre-market Tuesday after the company announced plans to discontinue the development of its lead asset NL-201 prompting Stifel to downgrade the stock to Hold from Buy. Neoleukin ( NLTX ) made the disclo...

Neoleukin Therapeutics press release ( NASDAQ: NLTX ): Q3 GAAP EPS of -$0.24 beats by $0.07 . Cash, cash equivalents, and short-term investments totaled $106.9 million as of September 30, 2022, compared to $142.5 million as of December 31, 2021. For further ...

-- Development of NL-201 to be discontinued for strategic reasons -- -- Company to focus on next-generation de novo proteins and core technology -- -- Company restructuring to extend cash runway into the second half of 2025 -- SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) ...

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming Americ...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Bank of America downgraded immunotherapy-focused Neoleukin Therapeutics, Inc. ( NASDAQ: NLTX ) to Underperform from Buy, arguing that the company offers limited upside potential in the near term as its lead candidate, NL-201 lacks enough catalysts. NL-201, designed to mimic ...

Turquoise Hill Resources ( TRQ ) -18% after Turquoise Hill rejects Rio Tinto's bid to take control of huge Mongolia mine . Arcadia Biosciences ( RKDA ) -18% to raise $5M in securities offering . Root ( ROOT ) -17% . TREASURE GLOBAL ( TGL ...

Neptune Wellness Solutions ( NEPT ) +48% . ADDvantage Technologies Group ( AEY ) +33% Technologies GAAP EPS of $0.07, revenue of $27.79M. Larimar Therapeutics ( LRMR ) +31% on plans to resolve clinical hold on lead asset. Twin Vee Powercats ...

The following slide deck was published by Neoleukin Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Neoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation